{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:42:01Z","timestamp":1778049721126,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bone.2017.09.005","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T18:47:22Z","timestamp":1505414842000},"page":"219-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Prevalence and risk factors for fragility fracture in systemic mastocytosis"],"prefix":"10.1016","volume":"105","author":[{"given":"Yannick","family":"Degbo\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Eischen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Nigon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pol-Andr\u00e9","family":"Apoil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Mailhol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Hanssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bulai-Livideanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bone.2017.09.005_bb0005","first-page":"215","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.bone.2017.09.005_bb0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.bone.2017.09.005_bb0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.bone.2017.09.005_bb0020","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2017.09.005_bb0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"van der Veer","year":"2012","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.bone.2017.09.005_bb0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","article-title":"Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis","volume":"134","author":"van der Veer","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.bone.2017.09.005_bb0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cea.12627","article-title":"Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis","volume":"46","author":"Bulai Livideanu","year":"2016","journal-title":"Clin. Exp. Allergy"},{"issue":"3","key":"10.1016\/j.bone.2017.09.005_bb0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A reference standard for the description of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2017.09.005_bb0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.bone.2017.09.005_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001906","article-title":"Phenotypic and genotypic characteristics of mastocytosis according to the age of onset","volume":"3","author":"Lanternier","year":"2008","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bone.2017.09.005_bb0055","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group","volume":"4","author":"Kanis","year":"1994","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bone.2017.09.005_bb0060","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2017.09.005_bb0065","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/ket007","article-title":"Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management","volume":"52","author":"Gregson","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.bone.2017.09.005_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/JCD:8:1:001","article-title":"Misinterpretation of osteodensitometry with high bone density","volume":"8","author":"Whyte","year":"2005","journal-title":"J. Clin. Densitom."},{"issue":"8","key":"10.1016\/j.bone.2017.09.005_bb0075","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00256-012-1374-9","article-title":"Advanced imaging of skeletal manifestations of systemic mastocytosis","volume":"41","author":"Fritz","year":"2012","journal-title":"Skelet. Radiol."},{"issue":"4","key":"10.1016\/j.bone.2017.09.005_bb0080","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2017.09.005_bb0085","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.bone.2017.09.005_bb0090","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejrad.2008.04.061","article-title":"Assessment of fracture risk","volume":"71","author":"Kanis","year":"2009","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"10.1016\/j.bone.2017.09.005_bb0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.bone.2017.09.005_bb0100","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaci.2014.05.047","article-title":"Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects","volume":"135","author":"Vos","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.bone.2017.09.005_bb0105","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","article-title":"Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis","volume":"124","author":"Laroche","year":"2011","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2017.09.005_bb0110","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaci.2013.06.019","article-title":"Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"132","author":"Rabenhorst","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.bone.2017.09.005_bb0115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaci.2012.11.008","article-title":"Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients","volume":"132","author":"Hartmann","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.bone.2017.09.005_bb0120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.bone.2017.09.005_bb0125","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2353\/ajpath.2009.080871","article-title":"Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts","volume":"174","author":"Biosse-Duplan","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.bone.2017.09.005_bb0130","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1073\/pnas.0934373100","article-title":"Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss","volume":"100","author":"Fitzpatrick","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bone.2017.09.005_bb0135","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1398-9995.2012.02809.x","article-title":"Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions","volume":"67","author":"van Doormaal","year":"2012","journal-title":"Allergy"},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2017.09.005_bb0140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02207246","article-title":"The osteoporosis of heparinotherapy and systemic mastocytosis","volume":"8","author":"Bardin","year":"1989","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.bone.2017.09.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124912","article-title":"Determination of plasma heparin level improves identification of systemic mast cell activation disease","volume":"10","author":"Vysniauskaite","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bone.2017.09.005_bb0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1210\/jcem-72-1-140","article-title":"Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study","volume":"72","author":"Chines","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2017.09.005_bb0155","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00198-013-2305-x","article-title":"Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis","volume":"24","author":"Seitz","year":"2013","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217303411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217303411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T06:08:08Z","timestamp":1539151688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328217303411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"alternative-id":["S8756328217303411"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2017.09.005","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and risk factors for fragility fracture in systemic mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2017.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}